Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007.

- Presentations on long-term safety and cardiovascular safety of nebulized formoterol fumarate and safety/ efficacy of concomitant use with tiotropium for treatment of COPD -

NAPA, Calif., Oct. 16 /PRNewswire/ -- Dey, L.P., a subsidiary of Mylan Inc. , announces three clinical data presentations will be given at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP) on Wednesday, October 24, 2007 at the McCormick Place Convention Center in Chicago. Data will be presented from two safety studies that were included as part of the New Drug Application (NDA) filing to the U.S. Food and Drug Administration (FDA) for Perforomist(TM) Inhalation Solution. The third presents results from a Phase IIIb study of the concomitant use of Perforomist(TM) Inhalation Solution with tiotropium for the treatment of COPD.

Perforomist(TM) Inhalation Solution is the first and only FDA-approved nebulized form of formoterol fumarate and is indicated for long-term, twice- daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD). Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.

For those attending CHEST, the three presentations are available as follows:

 
  -- "Long-Term Safety of Nebulized Formoterol in COPD: An Open-Label 
     Active-Control Extension Study" Poster # 239 
 
  -- "Cardiovascular Safety of Nebulized Formoterol in COPD Patients: A 
     Double-Blind, Placebo-Controlled Study" Poster # 238 
 
  -- "Safety and Efficacy of Concomitant Treatment with Nebulized Formoterol 
     and Tiotropium in COPD," Poster # 251 
 
  Poster viewing: Session ID 902 - COPD Treatment II 
  Wednesday, October 24, 2007, 12:30 - 2:00 PM